Vir Biotechnology, Inc. (VIR), a Healthcare Biotechnology business, saw its stock trade 24.95 common shares, a surge against to its 10-day trading volume of 1.5M.
Vir Biotechnology, Inc. (VIR) stock is changing hands at $24.35, down -2.28 cents or -8.56% on the day. Based on this we can see some traders are either waiting on the sidelines to get involved or perhaps some are taking losses.
Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus. Vir is working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV, also referred to as “Wuhan coronavirus”.
Total Revenue for Vir Biotechnology, Inc. (VIR) is $10.24M, Gross Profit is $-89.56M and the EBITDA is $-138.2M.
Vir Biotechnology, Inc. (VIR) Technical Evaluation:
The average 10-day trading volume of Vir Biotechnology, Inc. (VIR) is 1.5M compared to 271.37k over the last 3 months which indicates a slope in trading activity. Right now, Vir Biotechnology, Inc. (VIR) has a 50-day moving average of $15.27 and a 200-day moving average of $14.31. These moving averages are popular technical figures that investors use to analyze price trends of Vir Biotechnology, Inc. (VIR).
Approximately 1.46% of the shares of the company are short sold from traders betting the shares might trade lower. The beta value on Vir Biotechnology, Inc. (VIR) stock is -, indicating its 22.11% to 10.95% more volatile than the overall marketplace.
Technically, VIR’s short term support levels are around $25.08, $20.40 and $15.92 on the downside.
Based on technical analysis, VIR has short term rating of Neutral (0.16), Intermediate rating of Very Bullish (0.50) and the long-term rating of Neutral (0.03) giving it an overall rating of Neutral (0.23).
VIR is trading 128.58% off its 52 week low at $11.65 and -8.17% off its 52 week high of $29.00. Performance wise, VIR stock has recently shown investors 33.48% a surge in a week, 111.77% a surge in a month and 84.55% a surge in the past quarter.
More importantly, Vir Biotechnology, Inc. (VIR) has shown a return of 111.77% since the beginning of the year.
Vir Biotechnology, Inc. (VIR) Key Research:
Vir Biotechnology, Inc. (VIR) is a mid cap company with a market cap value of $2.737B. VIR insiders hold roughly 0.43% of the shares.
On Nov-05-19 Goldman Initiated VIR as Buy at $37. On Nov-05-19 JP Morgan Initiated VIR as Overweight at $25 and on Nov-14-19 Robert W. Baird Initiated VIR as Neutral.
There are currently 96.91M shares in the float and 96.91M shares outstanding. There are 1.46% shares short in VIRs float.
The industry rank for Vir Biotechnology, Inc. (VIR) is 83 out of 255 ranking it at the Top 33% .
Vir Biotechnology, Inc. (VIR) Fundamental Evaluation:
VIR last 2 years revenues have decreased from $10,668 to $10,237 showing a downtrend.
Wall Street expects Vir Biotechnology, Inc. (VIR) to report an EPS next Qtr loss of -0.67 and a profit of 19.90% next year.
The growth rate on VIR this year is NA compared to an industry 8.10. However, VIRs next year’s growth rate is -8.84 compared to an industry 8.10.
The book value per share (mrq) is -23.94 and cash per share (mrq) is 3.30. Giving them a price/book (mrq) of NA compared to an industry of 3.75 and VIRs price/cash flow (mrfy) is NA compared to an industry of 12.30.
VIR fundamental ratios shows an EPS growth vs. previous year -1.81 and EPS growth vs. previous quarter -0.47.
About Vir Biotechnology, Inc. (VIR):
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company’s development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.